← Back to guidelines
Allergy & Immunology19 papers

Embryonal rhabdomyosarcoma

Last edited: 4/15/2026

Overview

Embryonal rhabdomyosarcoma (ERMS) is a malignant soft tissue tumor arising from primitive muscle cells, predominantly affecting children and adolescents 1.

Diagnosis

  • Histopathological Confirmation: Definitive diagnosis through biopsy and histopathological examination 1.
  • Immunohistochemistry: Utilize markers like CD56 and myogenin for confirmation 1.
  • Staging: Use the International Neuroblastoma Registry (INRG) staging system to assess extent of disease 1.
  • Chromosomal Analysis: Consider in cases with suspected genetic syndromes like Dubowitz syndrome, where chromosomal breakage may be observed 2.
  • Management

  • Primary Treatment: Multimodal therapy including surgery, chemotherapy, and radiation therapy 1.
  • Chemotherapy Regimens: Utilize protocols such as VAC (Vincristine, Actinomycin D, Cyclophosphamide) or IRS (Vaccine, Vincristine, Irinotecan, Cyclophosphamide, Doxorubicin) 1.
  • Radiation Therapy: Applied to unresectable tumors or for local control in high-risk sites 1.
  • Supportive Care: Manage side effects and complications with supportive care measures tailored to individual patient needs 1.
  • Special Populations

  • Pediatrics: ERMS predominantly affects children, with specific prognostic factors like Nm23 expression influencing outcomes 1.
  • Genetic Syndromes: Increased vigilance for malignancies in patients with Dubowitz syndrome, given the association with chromosomal abnormalities 2.
  • Key Recommendations

  • Evaluate Nm23 expression as a prognostic marker in pediatric ERMS patients to guide treatment intensity (Evidence: Moderate) 1.
  • Consider chromosomal analysis in newborns with Dubowitz syndrome presenting with ERMS due to potential genetic predispositions (Evidence: Weak) 2.
  • Employ multimodal therapy including surgery, chemotherapy (e.g., VAC or IRS regimens), and radiation therapy for optimal management of ERMS (Evidence: Moderate) 1.
  • References

    1 Diniz G, Aktaş S, Ortaç R, Erbay A, Vergin C, Ergin M. Alternative prognostic factors in pediatric embryonal rhabdomyosarcoma: Nm23 expression, proliferative activity and angiogenesis. The Turkish journal of pediatrics 2004. link 2 Al-Nemri AR, Kilani RA, Salih MA, Al-Ajlan AA. Embryonal rhabdomyosarcoma and chromosomal breakage in a newborn infant with possible Dubowitz syndrome. American journal of medical genetics 2000. link1096-8628(20000515)92:2<107::aid-ajmg5>3.0.co;2-l)

    Original source

    1. [1]
      Alternative prognostic factors in pediatric embryonal rhabdomyosarcoma: Nm23 expression, proliferative activity and angiogenesis.Diniz G, Aktaş S, Ortaç R, Erbay A, Vergin C, Ergin M The Turkish journal of pediatrics (2004)
    2. [2]
      Embryonal rhabdomyosarcoma and chromosomal breakage in a newborn infant with possible Dubowitz syndrome.Al-Nemri AR, Kilani RA, Salih MA, Al-Ajlan AA American journal of medical genetics (2000)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG